APLS vs JNPR · rev $1.00B vs P/E 38, $13.36B cap
Apellis Pharmaceuticals Inc (APLS) versus Juniper Networks Inc (JNPR) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
Juniper Networks Inc (JNPR) is a communication equipment company listed on US.
Latest reported APLS revenue for 2025-12-31 was $1.00B. Net income was $22.4M. Revenue was up 28.5% from 2024-12-31 to 2025-12-31. APLS currently screens at market cap $2.29B.
JNPR does not have a complete income-statement cache yet.
APLS currently screens at market cap $2.29B. JNPR currently screens at market cap $13.36B and trailing P/E 38.0.
Not investment advice. Open the APLS and JNPR stock pages for the full models.
Not investment advice.